iTeos Therapeutics introduced a poster presentation of preclinical information on EOS-984, a possible first-in-class small molecule inhibitor focusing on the equilibrative nucleoside transporter 1 in oncology, on the American Affiliation for Most cancers Analysis Annual Assembly, being held April 5-10, 2024 in San Diego, California. Primarily based on the corporate’s discovery and characterization of ENT1 in adenosine-mediated immunosuppression, this novel mechanism permits for the intracellular accumulation of adenosine, which then suppresses proliferation and effector perform of T cells within the excessive adenosine tumor microenvironment. In mouse fashions, deletion of ENT1 led to potent management of tumor proliferation and elevated CD8+ T cell frequency, proliferation, and cytokine manufacturing inside tumors, additional supporting ENT1’s position in tumor progress. In preclinical research, blockade of intracellular adenosine accumulation by EOS-984 enabled proliferation of reminiscence T cells and TILs regardless of excessive adenosine concentrations, ensuing within the restoration of T cell perform and enhanced tumor cell killing. Moreover, mixture of EOS-984 with anti-PD-1 remedy synergistically led to the management of tumor progress in a humanized mouse mannequin of triple detrimental breast most cancers immune to anti-PD-1 blockade. Attributable to its mechanism of motion, EOS-984 holds potential as a mix associate past anti-PD-1 remedy, together with different immuno-oncology brokers, cell therapies, and bispecific T cell engagers. EOS-984 is at the moment within the dose escalation portion of a Section 1 trial in superior malignancies. Topline information from the Section 1 trial is anticipated within the second half of 2024.
Revealed first on TheFly – the last word supply for real-time, market-moving breaking monetary information. Strive Now>>
